OrbiMed Launches $600 Million Healthcare-Focused Fund

Sep 1 2011 | 10:48am ET

New York-based investment management firm OrbiMed Advisors has closed a new $600 million healthcare fund.

The Luxembourg-domiciled Royal Opportunities fund will invest worldwide in healthcare royalty streams and provide structured debt capital to healthcare companies. Investors in the fund include endowments, foundations and financial institutions.

OrbiMed has tapped three partners—Samuel D. Isaly, Sven H. Borho and W. Carter Neild—along with a dedicated team of four to oversee the fund.

“Life sciences companies are typically dependent on equity markets to raise new capital,” said Tadd Wessel, a managing director on the Royalty Opportunities team. “With this fund, OrbiMed can offer a minimally dilutive capital alternative to fund product launches, M&A opportunities, new product research, and general corporate purposes.”

OrbiMed, which focuses exclusively on the healthcare sector, has over $5 billion in assets under management. The firm employs over 50 professionals in offices in New York, San Francisco, Shanghai, Mumbai and Israel.


In Depth

Exotic Assets: Investing In Rare Violins

Jan 17 2017 | 4:43pm ET

By definition, alternative investments include exotic assets far beyond your typical...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

The Trump Administration: What It Could Mean for Carried Interest

Jan 19 2017 | 5:25pm ET

The arrival of the Trump administration brings the potential for a repeal of the...

 

From the current issue of

Versum Materials (VSM), with a market capitalization of $2.7 billion, enables chipmakers to achieve higher performance at lower cost with enhanced reliability. Versum is a leading global provider of electronic materials for the integrated circuit and flat-panel display markets.